Shots:
- The US FDA has approved Rapiblyk (landiolol) for use in pediatric pts (from birth to <18 years of age) with supraventricular tachycardia (SVT), expanding its use beyond adults
- Approval was supported by the LANDI-PED study (n=60), which showed >20% reduction in ventricular rate, demonstrating clinically meaningful heart rate control in this patient subgroup
- Rapiblyk is an IV, ultra-short-acting selective beta-1 blocker used in monitored hospital settings, with rapid onset & offset enabling precise, controlled heart rate management
Ref: Businesswire | Image: AOP Health | Press Release
Related News: Partner Therapeutics Reports the US FDA sBLA Submission of Bizengri for NRG1 Fusion Positive Cholangiocarcinoma
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
